IQVIA

Market Access

Hand arranging wooden cubes in a structure rocket shape. Conceptual of business startup and strategy.

Achieving launch excellence in orphan medicines

New rare disease treatments face a complex market access landscape that presents fundamental challenges for pharmaceutical companies seeking to achieve launch excellence.

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png

Market Access

Launch excellence in a disrupted world – challenges & opport...

Overview

Market Access

Orphan medicines launch excellence: sustaining launch succes...

Overview Launching orphan medicines excellently will become even more important over the next five years as more patients with rare diseases have pharmacotherapies available.

Views & Analysis

Simulated data, real-world patient insights

The UK has some of the best patient data available anywhere in the world, and a preeminent position in the collection of cancer data at both an individual tumour and patient level.

Views & Analysis

Biotech in post-Brexit Britain: the future for the UK’s phar...

Drug development can be quite a risky business at the best of times, but particularly in the biotech sector where companies may only have a few assets to their name.

Market Access

The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan

Overview

Achieving launch excellence in orphan medicines

Launch excellence in a disrupted world – challenges & opport...

Orphan medicines launch excellence: sustaining launch succes...

Simulated data, real-world patient insights

Biotech in post-Brexit Britain: the future for the UK’s phar...

The 2nd Life Sciences Sector Deal and the NHS 10 Year Plan

Praxis soars on rare childhood epilepsy trial data

How to meet your physicians where they are online

IQVIA

Editor's Picks